Reduced Diuretic Dose in Patients Treated With Eplerenone: Data From the EPHESUS Trial.
Fiche publication
Date publication
mai 2020
Journal
Circulation. Heart failure
Auteurs
Membres identifiés du Cancéropôle Est :
Pr ROSSIGNOL Patrick
Tous les auteurs :
Ferreira JP, Eschalier R, Duarte K, Damman K, Gustafsson F, Schou M, Girerd N, Fay R, Tala S, Pitt B, Zannad F, Rossignol P
Lien Pubmed
Résumé
Loop diuretics are used for congestion relief, and dose adaptations are usually a consequence of the clinicians' clinical judgement about the congestive status of the patient. In EPHESUS (Eplerenone in Patients With Systolic Dysfunction After Myocardial Infarction), many patients required diuretics for congestion relief. We thus hypothesized that blinded allocation to eplerenone would lead clinicians to reduce loop diuretics, as a consequence of the improvement in patients' status.
Mots clés
cardiomyopathies, diuretics, eplerenone, sodium potassium chloride symporter inhibitors
Référence
Circ Heart Fail. 2020 May;13(5):e006597